Proteus Digital Health

By HIMSS Media 02:54 pm June 26, 2020
In the newest episode of HIMSSCast, MobiHealthNews founding editor Brian Dolan, now founder and lead writer at Exits and Outcomes, joins the host, Jonah Comstock, Managing Editor Laura Lovett and Associate Editor Dave Muoio for a bit of a post-mortem on Proteus Digital Health, the sensor-enabled pill company that filed for Chapter 11 bankruptcy protection last week.     More related to this...
By Dave Muoio 02:51 pm June 16, 2020
Proteus Digital Health, maker of an ingestible sensor for tracking medication adherence, filed for Chapter 11 bankruptcy protection yesterday. The news comes months after word that the company had furloughed much of its staff, reassessed its high-profile partnership with Otsuka Pharmaceutical and shifted away from its primary focus area of mental disorder treatment. The "smart pill" maker...
By Dave Muoio 02:45 pm January 14, 2020
Following news of hardships at Proteus Digital Health, CEO Andrew Thompson has told STAT News that the company is winding down its high-profile $88 million deal with Otsuka Pharmaceutical, and will be pivoting from its current primary focus on mental disorders toward cancers and infectious disease treatments. The pharmaceutical company has now acquired the full license for Proteus’ mental health...
By Dave Muoio 05:01 pm December 13, 2019
It has been a tumultuous week in the realm of digital health partnerships. It started with word of Proteus Digital Health’s floundering business and failed investment round, which reports say was partially driven by cooling relations between the digital pill maker and its longtime patron Otsuka Pharmaceuticals. A few days later, Sanofi announced a company-wide strategy shift that found Onduo, its...
By Dave Muoio 04:03 pm December 9, 2019
Gainesville, Florida-based etectRx has received FDA 510(k) clearance for its ID-Cap System, a prescription ingestible system that sends adherence event logs to an external medical device. Similar to the system pioneered by etectRx’s high-profile competitor, Proteus Digital Health, the ID-Cap’s core is a standard capsule containing a sensor that transmits a message once it comes into contact with...
By Dave Muoio 01:03 pm December 9, 2019
Proteus Digital Health, maker of an ingestible sensor system for treatment adherence monitoring, was forced to furlough many of its employees last month after a $100 million funding round didn’t close as expected, according to a weekend report from CNBC. These employees were brought back after about two weeks after Proteus was able to secure $5 million in emergency funding, according to the...
By Dave Muoio 04:09 pm November 14, 2019
A new study suggests that Proteus Digital Health’s sensor-embedded pills can improve adherence among Hepatitis C (HCV) patients who are at a high risk for nonadherence. The data — presented this week at the American Association for the Study of Liver Diseases’ (AASLD) The Liver Meeting — indicate a 93% overall rate of medication adherence, and a 99.5% rate of sustained virologic response recorded...
By Dave Muoio 03:18 pm October 7, 2019
Proteus Digital Health’s ingestible pill and sensor system could improve medication adherence, and subsequently treatment, for patients with tuberculosis (TB), according to new data from an independent study conducted in California. Published Friday in PLoS Medicine, the trial found Proteus’ system to accurately determine whether or not a medication was taken. Patients using the system at home...
By Dave Muoio 12:34 pm January 17, 2019
In conjunction with Fairview Health Services and University of Minnesota Health, Proteus Digital Health unveiled plans to pair its sensor-equipped digital pills with an oral oncology therapeutic. According to an announcement from Proteus, the new care model is currently being used to treat stage 3 and stage 4 colorectal cancer patients receiving care at Fairview. There, clinicians are prescribing...
By Dave Muoio 04:23 pm October 15, 2018
Proteus Digital Health and Otsuka Pharmaceutical have expanded their partnership on digital therapeutics. On Thursday, Proteus announced that it received $88 million from the pharma company, which will go toward the continued development and commercialization of its ingestible sensor pill platform. Additionally, the five-year deal will also support the investigation of a wider digital medicine...